# HEC169096 in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05451602/  
OnCo record `nct05451602` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HEC169096 in advanced solid tumours, run by Sunshine Lake Pharma Co., Ltd., now recruiting.

## Summary

HEC169096 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05451602 by Sunshine Lake Pharma Co., Ltd., with 456 participants planned, started 2022-10-21 and due to reach its primary completion in 2026-12-30. Interventions recorded: HEC169096.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05451602
- Phase: 1/2
- Setting: Phase 1/2 Study of the Highly-selective RET Inhibitor,HEC169096 in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
- Sponsor: Sunshine Lake Pharma Co., Ltd.
- Enrolled: 456

## Sources

- ClinicalTrials.gov NCT05451602: https://clinicaltrials.gov/study/NCT05451602

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Sunshine Lake Pharma (HEC)](https://onco.cc/companies/sunshine-lake-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct05451602.json